Another bank impressed by early 2023 Wegovy prescriptions
US prescriptions for Novo Nordisk’s newest obesity drug, Wegovy, jumped two weeks into 2023, which Jyske Bank says indicate a strong sale.
by marketwire, translated by daniel pedersen
Novo Nordisk’s Wegovy, an obesity medicine, has seen prescription growth in the first two weeks of January, reflecting strong sales, says Henrik Hallengreen Laustsen, senior analyst at Denmark’s Jyske Bank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Norway denies Novo Nordisk reimbursement for obesity drug
For subscribers
